Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · IEX Real-Time Price · USD
14.28
-0.07 (-0.49%)
May 16, 2022 4:00 PM EDT - Market closed
Market Cap44.28B
Revenue (ttm)29.28B
Net Income (ttm)1.89B
Shares Out3.10B
EPS (ttm)1.08
PE Ratio13.20
Forward PE10.22
Dividend$0.40 (2.78%)
Ex-Dividend Daten/a
Volume2,593,767
Open14.24
Previous Close14.35
Day's Range14.20 - 14.32
52-Week Range13.17 - 17.56
Beta1.00
AnalystsBuy
Price Target16.11 (+12.8%)
Earnings DateMay 10, 2022

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia...

IndustryPharmaceuticals
Founded1781
CEOChristophe Weber
Employees47,099
Stock ExchangeNYSE
Ticker SymbolTAK
Full Company Profile

Financial Performance

In 2020, TAK's revenue was 3.20 trillion, a decrease of -2.84% compared to the previous year's 3.29 trillion. Earnings were 376.01 billion, an increase of 749.90%.

Financial numbers in millions JPYFinancial Statements

Analyst Forecast

According to 20 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 16.11, which is an increase of 12.82% from the latest price.

Price Target
$16.11
(12.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Japan's Takeda Pharma says full-year profit slid 9.5%

Takeda Pharmaceutical Co said on Wednesday that 12-month operating profit slid 9.5% from the previous year.

5 days ago - Reuters

Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products,...

5 days ago - Business Wire

Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in th...

2 weeks ago - Business Wire

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hosp...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular The...

3 weeks ago - Business Wire

Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfa...

4 weeks ago - Business Wire

Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Age...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of here...

4 weeks ago - Business Wire

Takeda Announces Completion of Acquisition of Own Shares

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today provided an update on the status and announced the completion of the acquisition of its own sh...

1 month ago - Business Wire

Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TA...

1 month ago - Business Wire

Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda and the New York Academy of Sciences announced the winners of the fourth Innovators in Science Award.

1 month ago - Business Wire

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting o...

1 month ago - Business Wire

Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelum...

1 month ago - Business Wire

3 Japanese Stocks to Diversify Your Portfolio

Japan has the world's third-largest economy, which has started to rebound from the pandemic. The Japanese economy expanded at a 5.4% annualized rate in the fourth quarter of 2021.

Other symbols:MSBHFTM
2 months ago - GuruFocus

Takeda Pharma: A Japanese Dividend Powerhouse

Takeda Pharmaceutical ( TAK , Financial) is Japan's largest R&D-focused biopharma company. Founded in 1781, this is an established company with a global presence.

2 months ago - GuruFocus

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioe...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--AAAAI Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

2 months ago - Business Wire

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The stu...

2 months ago - Benzinga

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analys...

OSAKA, Japan & CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed ...

2 months ago - Business Wire

Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda's Plasma-Derived Therapi...

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a manufacturing servic...

3 months ago - Business Wire

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topli...

3 months ago - Business Wire

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder

The FDA has approved Takeda Pharmaceutical Co Ltd's TAK Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disea...

3 months ago - Benzinga

FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living wi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von Willebrand ...

3 months ago - Business Wire

2 Dirt-Cheap Value Stocks to Buy Now

These two dividend-paying pharma stocks ought to be top performers in 2022.

Other symbols:VTRS
3 months ago - The Motley Fool

T. Rowe Price Japan Dumps Takeda Holding in 4th Quarter

The T. Rowe Price Japan Fund (Trades, Portfolio), part of Baltimore-based T.

3 months ago - GuruFocus

3 Healthcare Stocks With High Dividends

Looking for a healthcare stock that will pay you to own it? Here are three suggestions.

Other symbols:AMGNPETS
3 months ago - The Motley Fool

Takeda Named Global Top Employer for Fifth Consecutive Year

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer...

3 months ago - Business Wire

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthca...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with...

4 months ago - Business Wire